Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer
- Sander Mertens
- , Maarten A Huismans
- , Carla S Verissimo
- , Bas Ponsioen
- , Rene Overmeer
- , Natalie Proost
- , Olaf van Tellingen
- , Marieke van de Ven
- , Harry Begthel
- , Sylvia F Boj
- , Hans Clevers
- , Jeanine M L Roodhart
- , Johannes L Bos
- , Hugo J G Snippert
- University of Amsterdam; Hubrecht Institute-KNAW; University Medical Center Utrecht.
- Foundation Hubrecht Organoid Technology (HUB), Yalelaan 62, 3584 CM Utrecht, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the Netherlands.
- Cancer Genomics Netherlands, The Netherlands Cancer Institute , Amsterdam, the Netherlands.
- Oncode Institute
- Hubrecht Institute-KNAW (M.D.L., J.B.).
- Molecular Cancer Research, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.
Onderzoeksoutput: Bijdrage aan wetenschappelijk tijdschrift/periodieke uitgave › Artikel › Wetenschappelijk › peer review
61
Citaten
(Scopus)